Anti-leishmanial Effect of Itraconazole Niosome on in Vitro Susceptibility of Leishmania Tropica

Environ Toxicol Pharmacol. 2014 Jul;38(1):205-11. doi: 10.1016/j.etap.2014.04.003. Epub 2014 Jun 4.

Abstract

The novel niosomal system aimed to deliver the active drug entity to the target site. The objective of this study was to prepare and evaluate the effect of itraconazole niosome on the in vitro susceptibility of Leishmania tropica as compared to itraconazole alone or tartar emetic. The overall growth rate of promastigotes treated with various concentrations of itraconazole niosome was significantly lower than that of itraconazole alone (IC₅₀=0.24 μg/ml vs. IC₅₀=0.43 μg/ml, P<0.01). In contrast, the mean multiplication rate of amastigotes inside the macrophages and also the mean number of amastigotes in each macrophage treated with itraconazole niosome (34.9 and 3.0) were significantly lower (P<0.01) than those treated with itraconazole alone (62.0 and 3.8) or tartar emetic (63.9 and 4.2), respectively. These findings indicated that niosomes could be developed as a novel drug delivery for itraconazole in the in vitro model. Further studies are required to evaluate the effect of itraconazole niosome on volunteer human subjects.

Keywords: Itraconazole; Leishmania tropica; MTT assay; Macrophage model; Niosome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiprotozoal Agents / administration & dosage*
  • Cholesterol / chemistry
  • Drug Liberation
  • Hexoses / chemistry
  • Itraconazole / administration & dosage*
  • Leishmania tropica / drug effects*
  • Leishmania tropica / growth & development
  • Liposomes
  • Macrophages, Peritoneal / drug effects
  • Macrophages, Peritoneal / microbiology
  • Mice, Inbred BALB C

Substances

  • Antiprotozoal Agents
  • Hexoses
  • Liposomes
  • Itraconazole
  • Cholesterol
  • sorbitan monostearate